Business Context and Reporting Period
Company: Manhattan Pharmaceuticals, Inc. (Note: Request metadata listed "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Stage: Development Stage Company. The Company has not generated any product revenues.
Key Event: On March 8, 2010, the Company completed a merger with Ariston Pharmaceuticals, Inc., acquiring product candidates AST-726 (Vitamin B12 deficiency) and AST-915 (essential tremor). The Company also maintains a joint venture (Hedrin JV) for the development of a head lice treatment.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Income (Loss) | $41,247 | $258,414 | N/A |
| Operating Expenses | $515,631 | $1,570,166 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,075,966 |
| Total Assets | N/A | N/A | $19,034,882 |
| Total Liabilities | N/A | N/A | $24,770,122 |
| Stockholders' Deficiency | N/A | N/A | $(5,735,240) |
| Notes Payable (Total) | N/A | N/A | $18,216,338 |
Note: The reported net income for the nine-month period was primarily driven by a non-cash gain of $2,696,900 from the change in fair value of derivative liabilities, offsetting operating losses.
Material Changes vs. Prior Period
- Net Income vs. Loss: The Company reported a net income of $258,414 for the nine months ended September 30, 2010, compared to a net loss of $2,570,372 for the same period in 2009. This reversal is attributed to a $3.36 million favorable change in the fair value of derivative liabilities.
- Operating Expenses: Research and development expenses increased significantly to $305,500 (nine months 2010) from $57,154 (nine months 2009), driven by the commencement of development activities for the AST-726 project following the Ariston merger.
- Debt Obligations: Total notes payable increased substantially to $18.2 million from $1.9 million at December 31, 2009, due to the assumption of Ariston's debt ($15.5 million in 5% convertible notes) and the ICON convertible note.
- Assets: Total assets increased to $19.0 million from $365,662 at year-end 2009, primarily due to the acquisition of $17.7 million in in-process research and development (IPR&D) from Ariston.
Guidance, Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management states there is "substantial doubt" about the Company's ability to continue as a going concern. Cash on hand ($1.1 million) is sufficient only through the end of 2010. The Company lacks funds to repay $1.725 million in debt maturing in November 2010, December 2010, and February 2011. Failure to negotiate extensions or conversions could lead to default and bankruptcy.
- Financing Needs: The Company requires additional equity or debt financing to fund operations into 2011 and to conduct the pivotal Phase III trial for AST-726, estimated to cost between $1 million and $2 million.
- Joint Venture Disputes: Significant disputes exist with the Hedrin JV partner, Nordic Biotech, regarding anti-dilution calculations and capital contributions. Nordic has filed a Schedule 13D/A claiming beneficial ownership of 65.5% of the Company's stock, which the Company disputes (claiming 42.9%).
- Regulatory Risks: The Hedrin JV faces FDA inquiries regarding manufacturing and safety documentation that must be resolved before pivotal clinical trials can commence. The licensor, Thornton & Ross, has demanded assurances regarding the JV's financial ability to develop the product.
- Derivative Liability: The Company has significant derivative liabilities ($1.36 million current) associated with warrants and convertible notes containing "down-round" provisions, which fluctuate with the Company's stock price and impact net income/loss.
Investor Verification Checklist
- Debt Maturity: Verify the status of negotiations regarding the $1.725 million in debt maturing in late 2010 and early 2011 to assess default risk.
- Capital Raise: Confirm if the Company has secured the necessary funding to proceed with the AST-726 Phase III trial and sustain operations beyond 2010.
- Nordic Dispute: Monitor the resolution of the ownership and anti-dilution dispute with Nordic Biotech, as it impacts potential dilution and control of the Company.
- Hedrin JV Status: Assess the progress of the Hedrin JV in resolving FDA inquiries and the financial commitment of the JV to continue development.
- Derivative Accounting: Understand that reported net income is heavily influenced by non-cash changes in derivative liability fair values, not operational performance.